News round-up for 5-9 October, 2026 by Megan Thomas, Multimedia Editor at DDW. 

This week’s news roundup covers the upcoming Drug Discovery Innovators & Investors Conference in London, as well as some promising updates in cancer research and immunotherapy, particularly the development of new treatments and how immune cells respond to cancer.

The top stories: 

Full agenda announced for DDW’s London, UK Conference

DDW has announced the full agenda for its Drug Discovery Innovators & Investors (DDII) London, UK Conference – a full-day, in-person event focused on early-stage drug discovery and development.

Read more…

Cancer vaccine extends survival in glioblastoma trial

MimiVax and Roswell Park Comprehensive Cancer Center have announced results from the SURVIVE Phase IIb clinical trial evaluating novel cancer vaccine, SurVaxM, in patients with newly diagnosed glioblastoma.

Read more… 

Cancer Research UK and ORIC partner on CIP2A-targeted therapy

Cancer Research UK has signed an agreement with ORIC Pharmaceuticals to advance ORIC-259, a potential first-in-class CIP2A-targeted therapy, into clinical development.

Read more… 

First human trials in ovarian cancer for ‘armoured’ CAR-T therapy

Roswell Park Comprehensive Cancer Center and Generate Biomedicines have dosed the first patient in a first-in-human clinical trial evaluating GB-5267, an autologous IL‑18–armoured CAR T-cell therapy.

Read more… 

Immune cell behaviour challenges traditional classification

Researchers at the Francis Crick Institute, King’s College London and Complutense University of Madrid have shown that γδ T cells use adaptive immune receptors to drive rapid, innate-like responses to tissue stress, inflammation and cancer.

Read more…